The active ingredient in Adequan is polysulfated glycosaminoglycan (PSGAG), which is derived from bovine tracheal cartilage. It is specifically designed to halt the destructive processes of ...

Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and ...

Researchers tested a preclinical model for an experimental gene therapy designed to treat multiple sulfatase deficiency (MSD), a disorder that affects the brain, lungs, skin, and skeleton with no ...

The Laboratory establishes cell lines from skin biopsies for enzyme studies. The Laboratory also provides enzyme and/or urine glycosaminoglycan studies for monitoring patients who have been treated ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...

Researchers from Children's Hospital of Philadelphia (CHOP) tested a preclinical model for an experimental gene therapy ...

Tramiprosate is a glycosaminoglycan mimetic designed to bind to Aβ peptides, thereby stopping the formation of amyloid plaques. Owing to the short duration (3 months) of the tramiprosate Phase II ...

The red module may be beneficial in aging via the preferential degranulation of mast cells; release of glucosamines, heparin (a glycosaminoglycan) and histamine, which induce vasodilatation ...

US FDA approves Roche’s Ocrevus Zunovo to treat relapsing multiple sclerosis and PPMS: Basel Tuesday, September 17, 2024, 10:00 Hrs [IST] Roche announced that the United States ...

We are currently developing novel treatment strategies for CNS injuries based on the ability of HB-GAM and similar glycosaminoglycan-binding molecules to induce regenerative growth of neurites.